About US
Contact us
-
Mundipharma acquires rights to patents for heroin substitution from PhoenuxUK-based Mundipharma International has acquired exclusive global rights to a family of patents for heroin substitution, including a morphine/naloxone combination from Phoenux. In Europe about 1.4 mil2014/1/21
-
Gastrointe​stinal Therapeuti​cs Industry: Promising Drugs in Late-Stage Developmen​t Could Stabilise Declining Global MarketThe gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn’s disease (CD) in the eight major markets (8MM) — the US, UK, France, Germany, Ital2014/1/20
-
Zealand's partner Sanofi to start first Phase III study of LixiLan in Q1 2014Denmark-based Zealand Pharma has announced that the first LixiLan Phase III trial protocol has been approved, triggering a $15m payment from Sanofi. The payment was made by Sanofi under a licensing a2014/1/20
-
FDA accepts Iroko's Zorvolex sNDA for reviewThe US Food and Drug Administration (FDA) is to review Iroko Pharmaceuticals' supplemental new drug application (sNDA) for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug (NSAI2014/1/17
-
Roche Reports New Method for Efficiently Transporting Antibodies Across the Blood-Brain BarrierResults published in Neuron demonstrate efficacy in preclinical mouse models of Alzheimer's disease. The scientific journal Neuron has published results on the Roche-designed Brain Shuttle technolo2014/1/17
-
FDA approves AstraZeneca and BMS' diabetes drug FARXIGAThe US Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squibb's (BMS) FARXIGA (dapagliflozin), a once-daily oral treatment for the improvement of glycaemic control in adu2014/1/16
-
Chelsea obtains FDA panel recommendation for Northera for treatment of symptomatic nOHThe Food and Drug Administration's (FDA) cardiovascular and renal drugs advisory committee (CRDAC) voted 16-1 to recommend approval for Chelsea Therapeutics' Northera (droxidopa) to treat symptomatic2014/1/16
-
Bayer and Regeneron to develop potential drug for wet age-related macular degenerationBayer HealthCare and Regeneron Pharmaceuticals have agreed to collaborate on the development of a new antibody to platelet-derived growth factor receptor beta (PDGFR-ß) as a potential combinatio2014/1/15
-
Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus TherapeuticsEli Lilly and Companyhas announced that, based on positive PhaseII data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a poten2014/1/15
-
Alnylam buys Merck's Sirna TherapeuticsAlnylam Pharmaceuticals has acquired Merck's subsidiary Sirna Therapeutics, comprising intellectual property and RNAi assets, including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate2014/1/14